Who Paid My Doc
Luxturna
Biological Ocular
NDC 71394-415-01
General payments
$8,364,032
Research payments
$6,597,256
Through program year 2025, $8,364,032 in general payments and $6,597,256 in research payments were reported against Luxturna (Ocular).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $38 | 1 |
| 2025 | Research | $868,298 | 56 |
| 2024 | General | $197,357 | 61 |
| 2024 | Research | $767,491 | 52 |
| 2023 | General | $776,126 | 22 |
| 2023 | Research | $1,307,823 | 90 |
| 2022 | General | $1,217,843 | 128 |
| 2022 | Research | $970,751 | 91 |
| 2021 | General | $1,317,732 | 157 |
| 2021 | Research | $1,162,277 | 86 |
| 2020 | General | $1,181,145 | 80 |
| 2020 | Research | $634,733 | 45 |
| 2019 | General | $3,673,790 | 732 |
| 2019 | Research | $885,884 | 88 |
Breakdown
Each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
1,181 general · 508 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.